Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "alexion pharmaceuticals"

Shares of Alexion Pharmaceuticals Under Pressure, Down 2.5%

One of today's stocks on the move is Alexion Pharmaceuticals (NASDAQ:ALXN), down 2.5% to $181.20. The S&P is trading lower by 1.2% to 2,076 and the Dow is trading 1.4% lower Individual.com, 5 hours ago

14 images for alexion pharmaceuticals

American Banking News, 4 hours ago
ETF Channel, 4 days ago
Nasdaq, 4 days ago
Providence Business News, 3 weeks ago
Waterbury Republican American, 2 weeks ago
Jutia Group, 1 month ago
FOX 61, 1 month ago
PharmaceuticalProcessing, 1 month ago
Hartford Business Journal, 1 month ago
Waterbury Republican American, 1 month ago

Alexion Pharmaceuticals (ALXN) Trading Near $181.04 Support Level

Alexion Pharmaceuticals Inc ( ALXN ) traded between $182.78 and $186.89 before closing at $185.79 Thursday and presents some attractive trading opportunities today according to MarketIntelligenceCenter.com's patented algorithms. The computer program ...
 TradingCharts.com10 hours ago Alexion Pharmaceuticals (ALXN) Showing Resistance Near $187.79  Individual.com3 days ago Potential Alexion Pharmaceuticals (ALXN) Trade Has 6.86% Downside Protection  Individual.com2 weeks ago
[x]  

Watch for Alexion Pharmaceuticals to Potentially Rebound After Falling 1.14% Yesterday

(Comtex SmarTrend(R)) Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $178.65 to a high of $184.60. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $179.44 on volume ...
 Individual.com3 days ago Look for Shares of Alexion Pharmaceuticals to Potentially Rebound after Yesterday's 1.50% Sell Off  TradingCharts.com1 week ago Alexion Pharmaceuticals Rises 3.42% on Heavy Volume: Watch For Potential Pullback  TradingCharts.com3 weeks ago Alexion Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 5.78%  Individual.com1 month ago
[x]  

Pharmacyclics Could Very Well Be The Next Alexion Pharmaceuticals

Feb. 23, 2015 10:52 AM ET | About: Pharmacyclics, Inc. (PCYC), Includes: ALXN, JNJ by: Investing Healthcare Summary PCYC is seen by many investors as being too expensive. Despite PCYC developing different types of drugs than ALXN, there are ...
 Seeking Alpha1 week ago

SC 13G - ALEXION PHARMACEUTICALS INC (0000899866) (Subject)

Document Format Files Seq Description Document Type Size 1 alexionpharmainc.htm SC 13G 38109 Complete submission text file
 SEC3 weeks ago 10-K - ALEXION PHARMACEUTICALS INC (0000899866) (Filer)  SEC4 weeks ago

Alexion Pharmaceuticals has Relatively Underperformed its Peers in the Biotechnology Industry (ALXN, MYGN, ALKS, ISIS, INFI)

(Financial News Network On) Below are five companies in the Biotechnology industry that underperformed yesterday on a relative basis. This analysis was compiled based on yesterday's trading activity as we search for stocks that have could possible ...
 Individual.com2 weeks ago Shares of Pharmacyclics Rank the Lowest in Terms of Projected Earnings Growth in the Biotechnology Industry (PCYC, AMGN, ALXN, REGN, EBS)  Comtex SmarTrend2 weeks ago
4 Traders

Alexion Pharmaceuticals Inc. (ALXN) Release: FDA Grants Priority Review For Asfotase Alfa As A Treatment For Patients With Hypophosphatasia 3/2/2015

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Company's Biologics License Application (BLA) for asfotase alfa, an ...
 ClinicSpace4 days ago Alexion: FDA Grants Priority Review for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia  Individual.com1 day ago Alexion Pharmaceuticals Inc. Release: FDA Grants Priority Review For Asfotase Alfa As A Treatment For Patients With Hypophosphatasia  BioSpace3 days ago FDA Grants Priority Review for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia  TMC Net4 days ago
[x]  

Alexion Pharmaceuticals (ALXN) Q4 2014 Results - Earnings Call Webcast

The following audio is from a conference call that will begin on January 29, 2015 at 10:00 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Source: How did this change your view of ? More ...
 Seeking Alpha1 month ago Xencor's (XNCR) CEO Bassil Dahiyat on Q4 2014 Results - Earnings Call Transcript  Seeking Alpha2 weeks ago

Alexion Pharmaceuticals Guides Below Estimates

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) said it expects 2015 non-GAAP earnings of $5.60 to $5.80 per share on revenue of $2.55 billion to $2.60 billion. The current consensus earnings estimate is $5.91 per share on revenue of $2.72 billion for ...
 Individual.com1 month ago

Alexion Pharmaceuticals beats by $0.01, beats on revenue

How did this change your view of ? More Bullish More Bearish It Didn't This impact ( ) More Bullish More Bearish Unchanged Thanks for sharing your thoughts. Submit & View Results Skip to
 Seeking Alpha1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - alexion pharmaceuticals
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less